Washington University Institute of Clinical Translational Sciences

华盛顿大学临床转化科学研究所

基本信息

  • 批准号:
    9889200
  • 负责人:
  • 金额:
    $ 935.96万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2017
  • 资助国家:
    美国
  • 起止时间:
    2017-06-19 至 2022-02-28
  • 项目状态:
    已结题

项目摘要

The Washington University (WU) Institute of Clinical and Translational Sciences (ICTS) has transformed clinical and translational science and research education in our region, and fostered productive scientific collaborations with our hub partner institutions University of Missouri-Columbia, Saint Louis University, St. Louis College of Pharmacy, BJC HealthCare, Barnes Jewish Hospital, and St. Louis Children's Hospital. The ICTS now proposes innovative aims that align well with the goals of the CTSA network, and will together catalyze discovery and advance research findings into real-world implementation to improve health and health care. 1. Provide interdisciplinary programs to develop, promote, and retain highly qualified and diverse faculty, trainees, and staff who can translate scientific discoveries into action. We will tailor our efforts to the needs of individuals, promote formation of transdisciplinary, inter-institutional, and inter-hub teams, rigorously assess our programs, and draw on our institutional and regional strengths in genomics, dissemination and implementation, and entrepreneurship. WORKFORCE DEVELOPMENT 2. Facilitate research that is designed for implementation by engaging diverse communities and stakeholders in collaborative teams at all stages of the translational research process. We will partner with patient advocates, propel the science of community and stakeholder engagement, break down barriers to allow integration of research findings into clinical practice, and capitalize on our local entrepreneurial ecosystem to apply discoveries to improve community health. COLLABORATION AND ENGAGEMENT 3. Integrate research across the lifespan and promote translational science within complex populations. The ICTS will address health disparities and differences in disease manifestations across different ages and among special populations, address both urban and rural populations, catalyze formation of transdisciplinary teams, and evaluate the clinical, community, and entrepreneurial outcomes of our researchers' work. INTEGRATION 4. Drive innovation, quality, and efficiency in the translational research, by using best practices and streamlined institutional processes to support high quality multi-center clinical trials and developing new methodological approaches to facilitate translational research. METHODS AND PROCESSES 5. Apply innovative informatics solutions to improve quality and efficiency at every stage of translational research, and create an ecosystem that integrates diverse data and facilitates the interoperability, use, and reuse of digital assets. INFORMATICS Successful completion of these aims will transform regional research, dissemination, and workforce development and will apply the considerable resources of WU and its partners to national CTSA goals to advance clinical and translational science and improve human health.
华盛顿大学(WU)临床和转化科学研究所(ICTS)已经转变为 在我们地区的临床和转化科学和研究教育,并培养了生产性的科学 与我们的中心合作伙伴机构密苏里大学-哥伦比亚大学,圣刘易斯大学,圣路易斯大学, 路易斯药学院、BJC医疗保健、巴恩斯犹太医院和圣路易斯儿童医院。的 信通技术服务现在提出了与CTSA网络的目标相一致的创新目标, 促进发现并将研究成果推进到现实世界的实施中,以改善健康和健康 在乎 1.提供跨学科课程,以发展,促进和保留高素质和多样化 教师,学员和工作人员谁可以将科学发现转化为行动。我们将调整我们的努力, 个人的需求,促进跨学科,跨机构和跨枢纽团队的形成, 严格评估我们的项目,并利用我们在基因组学方面的机构和地区优势, 传播和执行以及创业精神。劳动力发展 2.促进旨在通过吸引不同社区参与实施的研究, 在翻译研究过程的各个阶段的合作团队的利益相关者。我们将合作 与患者倡导者一起,推动社区和利益相关者参与的科学,打破障碍, 允许将研究成果融入临床实践,并利用我们当地的企业 生态系统应用新发现来改善社区健康。合作与参与 3.整合整个生命周期的研究,并在复杂的环境中促进转化科学 人口。信息和通信技术将解决健康差距和疾病表现的差异, 不同年龄和特殊人群,解决城市和农村人口, 跨学科团队,并评估我们的临床,社区和创业成果 研究人员的工作。一体化 4.通过使用最佳实践, 简化机构流程,以支持高质量的多中心临床试验,并开发新的 方法论的方法,以促进翻译研究。方法和过程 5.应用创新的信息学解决方案,提高每个阶段的质量和效率 转化研究,并创建一个生态系统,整合不同的数据,并促进 数字资产的互操作性、使用和重用。信息学 成功完成这些目标将改变区域研究、传播和劳动力 发展,并将运用WU及其合作伙伴的大量资源来实现国家CTSA目标, 推进临床和转化科学,改善人类健康。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

William G. Powderly其他文献

Trimetrexate with leucovorin versus trimethoprim-sulfamethoxazole for moderate to severe episodes of Pneumocystis carinii pneumonia in patients with AIDS: a prospective, controlled multicenter investigation of the AIDS Clinical Trials Group Protocol 029/031.
三甲曲沙联合甲酰四氢叶酸与甲氧苄氨嘧啶-磺胺甲恶唑治疗艾滋病患者中度至重度卡氏肺孢子虫肺炎发作:艾滋病临床试验组方案 029/031 的一项前瞻性、对照多中心研究。
  • DOI:
    10.1093/infdis/170.1.165
  • 发表时间:
    1994
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Fred R. Sattler;Peter T. Frame;R. Davis;Larry Nichols;Brent Shelton;B. Akil;Robert P. Baughman;C. Hughlett;Walter Weiss;C. Boylen;C. V. D. Horst;John H. Black;William G. Powderly;Roy T. Steigbigel;J. Leedom;Henry Masur;Judith Feinberg
  • 通讯作者:
    Judith Feinberg
Cyclic AMP Cyclic GMP VASCULAR tone isregulated by a variety of vasoactive mol cules : neurotransmitters
Cyclic AMP Cyclic GMP 血管张力受多种血管活性分子:神经递质调节
  • DOI:
  • 发表时间:
    2008
  • 期刊:
  • 影响因子:
    0
  • 作者:
    P. Tebas;A. Patick;E. Kane;Michael Klebert;Janet H. Simpson;Alejo Erice;William G. Powderly;Keith Henry
  • 通讯作者:
    Keith Henry
When to start antiretroviral therapy: asking the right question
何时开始抗逆转录病毒治疗:提出正确的问题
  • DOI:
    10.2217/fvl.11.26
  • 发表时间:
    2011
  • 期刊:
  • 影响因子:
    3.1
  • 作者:
    William G. Powderly
  • 通讯作者:
    William G. Powderly
Virologic responses to a ritonavir--saquinavir-containing regimen in patients who had previously failed nelfinavir.
先前奈非那韦治疗失败的患者对含利托那韦-沙奎那韦疗法的病毒学反应。
  • DOI:
  • 发表时间:
    1999
  • 期刊:
  • 影响因子:
    0
  • 作者:
    P. Tebas;A. Patick;E. Kane;Michael Klebert;Janet H. Simpson;Alejo Erice;William G. Powderly;Keith Henry
  • 通讯作者:
    Keith Henry
Symptomatic cytomegalovirus infection in renal transplant recipients given either Minnesota antilymphoblast globulin (MALG) or OKT3 for rejection prophylaxis.
接受明尼苏达抗淋巴细胞球蛋白 (MALG) 或 OKT3 预防排斥反应的肾移植受者出现症状性巨细胞病毒感染。
  • DOI:
  • 发表时间:
    1993
  • 期刊:
  • 影响因子:
    13.2
  • 作者:
    Thomas C. Bailey;William G. Powderly;Gregory A. Storch;Stephen B. Miller;John D. Dunkel;Robert S. Woodward;Edward Spitznagel;D. Hanto;W. Claiborne Dunagan
  • 通讯作者:
    W. Claiborne Dunagan

William G. Powderly的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('William G. Powderly', 18)}}的其他基金

Washington University Institute of Clinical and Translational Sciences
华盛顿大学临床与转化科学研究所
  • 批准号:
    10827727
  • 财政年份:
    2023
  • 资助金额:
    $ 935.96万
  • 项目类别:
Washington University Institute of Clinical and Translational Sciences
华盛顿大学临床与转化科学研究所
  • 批准号:
    10700256
  • 财政年份:
    2022
  • 资助金额:
    $ 935.96万
  • 项目类别:
WASHINGTON UNIVERSITY INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCES
华盛顿大学临床与转化科学研究所
  • 批准号:
    10321102
  • 财政年份:
    2017
  • 资助金额:
    $ 935.96万
  • 项目类别:
Washington University Institute of Clinical and Translational Sciences
华盛顿大学临床与转化科学研究所
  • 批准号:
    10556449
  • 财政年份:
    2017
  • 资助金额:
    $ 935.96万
  • 项目类别:
Washington University Institute of Clinical and Translational Sciences
华盛顿大学临床与转化科学研究所
  • 批准号:
    10598597
  • 财政年份:
    2017
  • 资助金额:
    $ 935.96万
  • 项目类别:
WU INSTITUTE OF CLINICAL AND TRANSLATIONAL SCIENCES
吴氏临床与转化科学研究所
  • 批准号:
    10217859
  • 财政年份:
    2017
  • 资助金额:
    $ 935.96万
  • 项目类别:
Rosiglitazone & Exercise Training: Effects on HIV-Infected People
罗格列酮
  • 批准号:
    6971952
  • 财政年份:
    2004
  • 资助金额:
    $ 935.96万
  • 项目类别:
STUDY OF ONCE-WEEKLY ALENDRONATE IN HIV-INFECTED SUBJECTS
HIV 感染者每周一次阿仑膦酸钠的研究
  • 批准号:
    6971984
  • 财政年份:
    2004
  • 资助金额:
    $ 935.96万
  • 项目类别:
WU 122: EVALUATE METABOLIC EFFECTS OF DISCONTINUATION OF ANTIRETROVIRAL THERAPY
WU 122:评估停止抗逆转录病毒治疗的代谢影响
  • 批准号:
    6971971
  • 财政年份:
    2004
  • 资助金额:
    $ 935.96万
  • 项目类别:
CORE--CLINICAL FACILITY
核心——临床设施
  • 批准号:
    6649912
  • 财政年份:
    2002
  • 资助金额:
    $ 935.96万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 935.96万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 935.96万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 935.96万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 935.96万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 935.96万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 935.96万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 935.96万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 935.96万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 935.96万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 935.96万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了